Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease H and integrase: "Killing two birds with one stone"

Current Pharmaceutical Design

Volumn 10, Issue 30, 2004, Pages 3713-3723

  Andreola, Marie Line ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Cross inhibition; HIV 1 replication; Integrase; Polynucleotidyltransferase family; RNase H; Topoisomerase

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; 4 CHLOROPHEHYLHYDRAZONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; CAFFEIC ACID; CAMPTOTHECIN; COMPLEMENTARY DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELLIPTINIUM; INTEGRASE; INTEGRASE INHIBITOR; L 708906; MITOXANTRONE; OLIGONUCLEOTIDE; PROTEIN KINASE INHIBITOR; QUERCETIN; RECOMBINASE; RIBONUCLEASE H; RIBONUCLEASE H INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CATALYSIS; DNA BINDING; DNA SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION;

ANTI-HIV AGENTS; ENZYME INHIBITORS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MOLECULAR STRUCTURE; RIBONUCLEASE H, CALF THYMUS; VIRUS REPLICATION;

EID: 6944235757     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382648     Document Type: Review

References (51)

1. Hostomsky Z, Hostomska Z, Matthews DA. In Line SM Ed, Nucleases, Cold Spring Harbor: NY, 1993; 341.
2. Champoux JJ In Skalka AM and Goff SP Eds, Reverse transcriptase, Cold Spring Harbor: NY 1993; 103.
3. Kanaya S In: Crouch RJ, Toulmé JJ eds, Research in Ribonucleases H. Les Editions INSERM, 1998; 1-37.
4. Hansen J, Schulze T, Moelling K. RNase H activity associated with bacterially expressed reverse transcriptase of human T-cell lymphotropic virus III/lymphadenopathy-associated virus. J Biol Chem 1987; 262:12393-6.
5. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256:1783-90
6. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993; 90:6320-4.
7. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995; 2:293-302.
8. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B, et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1999; 92:1222-6
9. Davies JF, Hostomska Z, Hostomsky Z, Jordan SR, Matthews DA. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 1991; 252:88-95
10. Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organisation, conformational changes, and catalysis. Adv Virus Res 1999; 52:351-69.
11. Zheng R, Jenkins TM, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerisation and enhances catalytic activity. Proc Natl Acad Sci USA 1996; 93:13659-64.
12. 2+ promotes the file self-association of human immunodeficiency virus type-1 integrase in vitro. Biochemistry 1997; 36:173-80.
13. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigic R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266:1981-6.
14. Chen JC, Kruchiski J, Miercke LJ, Finer-Moore JS, Tang AH, Leavitt AD, Stroud RM. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci USA 2000; 97:8233-8.
15. Wang JY, Ling H, Yang W, Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organisation in the intact protein EMBO J 2001; 20:7333-43.
16. Fouchier RA, Malim MH. Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Adv Virus Res 1999; 52: 275-99.
17. Miller MD, Wang B, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes containing discontinuous plus strands are competent to integrate in vitro. J Virol 1995; 69:3938-44.
18. Yang W, Steitz TA. Recombining the structures of HIV integrase, RuvC and RNase H. Structure 1995; 3:131-4.
19. Rice P, Craigie R, Davies DR. Retroviral integrases and their cousins. Curr Opin Struct Biol 1996; 6:76-83.
20. Neamati N, Marchand C, Pommier Y. HIV-1 integrase inhibitors: past, present and future. Adv Pharmacol 2000; 49:147-65.
21. Fesen MR, Kohn KW, Leteurtre F, Pommier Y: Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci USA 1993; 90:2399-403.
22. Mazumder A, Gazit A, Levitzki A, Nicklaus M, Yung J, Kohlhagen G, Pommier Y. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochemistry 1995; 34:15111-22.
23. Carteau S, Mouscadet JF, Goulaouic H, Subra F, Auclair C. Effect of topoisomerase inhibitors on the in vitro HIV DNA integration reaction. Biochem Biophys Res Commun 1993; 192:1409-14.
24. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, et al. Structure ofthe HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 1999; 96:13040-3.
25. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-50.
26. Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR Jr, et al. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem 2002; 277:12596-603.
27. Pais GC, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, et al. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J Med Chem 2002; 45:3184-94.
28. Espeseth AS, Felock P, Wolfe A, Witmer M, Grobler J, Anthony N, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000; 97:11244-9.
29. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 2002; 99:6661-6.
30. Tomassini JE, Davies ME, Hastings JC, Lingham R, Mojena M, Raghoobar SL, et al. A novel antiviral agent, which inhibits the endonuclease of influenza viruses. Antimicrob Agents Chemother 1996; 40:1189-93.
31. Andreola ML, Pileur F, Calmels C, Ventura M, Tarrago-Litvak L, Toulme JJ, et al. DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry 2001; 40:10087-94.
32. de Soultrait VR, Lozach PY, Altmeyer R, Tarrago-Litvak L, Litvak S, Andreola ML. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J Mol Biol 2002; 324:195-203.
33. Jing N. Developing G-quartet oligonucleotides as novel anti-HIV agents: focus on anti-HIV drug design. Expert Opin Investig Drugs 2000; 9:1777-85.
34. Shaw-Reid CA, Munshi V, Graham P, Wolfe A, Witmer M, Danzeisen R, et al. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem 2003; 278:2777-80.
35. Kinoshita S, Chen BK, Kaneshima H, Nolan GP. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 1998; 95:595-604.
36. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995; 1:330-6.
37. Priel E, Showalter SD, Blair DG. Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase 1 inhibitor. AIDS Res Hum Retroviruses 1991; 7:65-72.
38. Jardine D, Tachedjian G, Locarnini S, Birch C. Cellular topoisomerase I activity associated with HIV-1. AIDS Res Hum Retroviruses 1993; 9:1245-50.
39. Takahashi H, Sawa H, Hasegawa H, Sata T, Hall W, Kurata T. Binding and dissociation of human topoisomerase I with hairpinloop RNAs: implications for the regulation of HIV-1 replication. Biochem Biophys Res Commun 2002; 297:593-9.
40. Shoya Y, Tokunaga K, Sawa H, Maeda M, Ueno T, Yoshikawa T, et al. Human topoisomerase I promotes HIV-1 proviral DNA synthesis: implications for the species specificity and cellular tropism of HIV-1 infection. Proc Natl Acad Sci USA 2003; 100:8442-7.
41. Arimondo PB, Riou JF, Mergny JL, Tazi J, Sun JS, Garestier T, et al. Interaction of human DNA topoisomerase I with G-quartet structures. Nucleic Acids Res 2000; 28(24):4832-8.
42. Jing N, Marchand C, Liu J, Mitra R, Hogan ME, Pommier Y. Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in vitro. J Biol Chem 2000; 275:21460-7.
43. Rando RF, Qjwang J, Elbaggari A, Reyes GR, Tinder R, McGrath MS, et al. Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides, which form intramolecular tetrads. J Biol Chem 1995; 270:1754-60.
44. Marchand C, Pourquier P, Laco GS, Jing N, Pommier Y. Interaction of human nuclear topoisomerase I with guanosine quartet-forming and guanosine-rich single-stranded DNA and RNA oligonucleotides. J Biol Chem 2002; 277:8906-11.
45. Takahashi H, Sawa H, Hasegawa H, Shoya Y, Sata T, Hall WW, et al. Topoisomerase I and ATP activate cDNA synthesis of human immunodeficiency virus type 1. Biochem Biophys Res Commun 2002; 294:509-17.
46. Cheng C, Kussie P, Pavletich N, Shuman S. Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases. Cell 1998; 92:841-50.
47. Melek M, Jones JM, O'Dea MH, Pais G, Burke TR Jr, Pommier Y, et al. Effect of HIV integrase inhibitors on the RAG1/2 recombinase Proc Natl Acad Sci USA 2002; 99:134-7.
48. Coffin JM, Hughes SH, Varmus HE Ed. In Retroviruses, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1997.
49. Dayam R, Neamati N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr Pharm Design 2003; 9(22): 1789-802.
50. Nair V. Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents. Curr Pharm Design 2003; 9(31): 2553-65.
51. Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, et al. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical spproaches. Curr Pharm Design 2002; 8(8): 595-614.